Ian Goodfellow
Department of Pathology, University of Cambridge, UK

Working in collaboration with the Wellcome Trust Sanger Centre and Public Health England, we have installed an Ion PGM sequencer in Makeni, Sierra Leone to provide sequence data of new ebola viral isolates.


Peter Schneider
Institute of Legal Medicine, Cologne, Germany

Peter M. Schneider is a full professor at the Institute of Legal Medicine, University of Cologne, Germany, where he is head of the Division of Forensic Molecular Genetics. He is responsible for the education of students in medicine, biology, and law, and performs routine DNA typing for criminal evidence material, identification cases, as well as relationship testing.

AJ McKnight
Queen's University Belfast, UK

Dr AJ McKnight runs the non-malignant inherited disease research labs for Queen’s University in Northern Ireland. Her primary research interest is chronic kidney disease, but she facilitates research into multiple conditions using high throughput genetics analysis approaches.


Hannah Stewart
Stratified Medicine Scotland, UK

SMS-IC is a consortium of industrial partners, four medical schools and four health boards with the aim of identifying new disease-associated biomarkers to improve future clinical treatment of disease.


Adam Ameur
National Genomics Infrastructure at Science for Life Laboratory, Uppsala University, Sweden

Adam will present his experiences and data on a range of genetic study applications using the latest Ion Torrent™ technology.


Inger Jonasson
National Genomics Infrastructure at Science for Life Laboratory, Uppsala University, Sweden

Inger’s team at Uppsala has been a long-standing partner for early access testing of Ion Torrent instruments and kits. The Uppsala results of transcriptome and exome studies using new Ion Torrent products will be a feature of the Ion World Tour 2015.


Sara Alvarez de Andrés
NIM Genetics, Madrid, Spain

As Medical Director for NIMGenetics, Dr Alvarez focuses on the implementation of exome sequencing in neuropediatrics. She brings a lot of experience with sequencing strategy related to different rare and inherited disorders and presents her work on whole exome sequencing for inherited disease mutation detection.


Aldo Scarpa
Department of Pathology and Diagnostics, University of Verona, Italy

Prof Scarpa is a founder member of the Onconetwork consortium, and was instrumental in the design and verification of the lung and colon and RNA fusion Ion AmpliSeq™ cancer panels, now CE/IVD labeled for diagnostic use. His work includes deep sequencing of solid tumour FFPE samples to investigate mutation status and correlation to clinical phenotypes, using the latest Ion Torrent technology.

Luis Alcaraz
BioArray, Alicante, Spain

Bioarray is a technology-based firm, specialized in genetic analysis through cutting-edge technologies in Molecular Biology, primarily DNA microarrays/CGH and NGS. Dr Alcaraz will present their work on preimplantation genetic screening using the Ion PGM™ System.


Andy Felton
Head of Product Management, Ion Torrent™ products, Thermo Fisher Scientific

Andy oversees the development of all Ion Torrent instruments and consumables products, from the Ion PGM™, Proton™ and Chef™ Systems, to Ion AmpliSeq™ panels and the Ion PII™ chip. He will present the very latest product developments and his team will be on hand to answer your questions.


José Costa
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Portugal

Dr Costa has a wealth of experience with next generation sequencing technology for cancer mutation detection. His team have been instrumental in the early testing phases of many Ion Torrent products. He will present their recent experiences with the Ion Chef™ automated sequencing preparation and cancer gene panel workflows.

Mattias Mild
Folkhälsomyndigheten Laboratorieutveckling, Sweden

The Public Health Agency of Sweden is an expert authority that has responsibility for public health issues at a national level. The agency develops and supports activities to promote health, prevent illnesses and improve preparedness for health threats. Mattias will present his work on epidemiology studies using Ion Torrent™ sequencing.

Adam Vivian-Smith
Norwegian Forest and Landscape Institute, Norway

Using Ion Torrent sequencing to enable forestry and forestry-related environmental studies.

Matthew Baranski
NOFIMA, Tromsø, Norway

NOFIMA is one of the largest institutes for applied research within the fields of fisheries, aquaculture and food research in Europe. Matthew works in the area of QTL mapping, molecular marker development and marker-assisted selection in a number of aquaculture species.

Peter Johansen
Department of Clinical Genetics, University Hospital, Copenhagen

Development of a method to detect autosomal trisomies, using semi-conductor sequencing and WISECONDOR for analysis.


Damian Bond
Prokyma, UK

We describe a leukocyte isolation method and next generation sequencing of oncogenic mutations in Circulating Tumour Cells (CTCs) isolated from blood.


Marco Loddo
Oncologica, UK

We discuss adoption of cancer precision medicine into European Cancer Networks using the next generation Ion PGM™ System and the Oncomine Focus Panel (OCP) to detect actionable driver mutations in all major tumour types.


Luca Quagliata
Institute of Pathology, University Hospital Basel, Switzerland

Molecular pathology laboratories are now facing a transition from classical Sanger-based sequencing to NGS. Here, we provide some examples from our experience during this phase and some possible near to come future applications.

Björn Menten
Centrum voor Medische Genetica, Gent, Belgium

Presenting copy number analysis by shallow whole genome sequencing (CNVseq) for preimplantation genetic screening and cell free DNA analysis.


Vladimir Strelnikov
Head of the Epigenetics Lab, Research Centre for Medical Genetics, Moscow, Russia

We have analysed mutations in a wide panel of genes involved in angiomyolipoma tumorigenesis by high throughput parallel sequencing.

Dmitry Korostin
Head of High-throughput Sequencing Group, Laboratory of Methods of Molecular Genetics, VI Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Russia

Development of an NGS technique for analysis of aneuploidies of chromosomes 18, 21 and X from cfDNA.

Alexander Lavrov
Research Center for Medical Genetics, Moscow, Russia

We are studying Chronic Myeloid Leukemia (CML) to identify new biomarkers for future disease monitoring and the development of new drugs.

Sylvie Bannwarth
Hôpital Archet 2, Molecular Genetics Laboratory, Nice, France

Development of future mitochondrial disease diagnostics using next generation sequencing of human mtDNA.

Paul Hofman
Laboratory of Clinical and Experimental Pathology, University of Nice Sophia Antipolis, France

Evaluation of NGS for ALK status assessment, from both tissue and liquid biospecimens in late stages non small cell lung carcinoma research.

Carlos Cortijo
Genetracer Biotech, Santander, Spain

GeneTracer is the only dual certification service provider in exomes and transcriptomes from Thermo Fisher Scientific in Spain, UK and Morocco. We offer a full range of genomic services to pharmaceutical companies, hospitals and research centres.

Carolina Dominguez
Hospital de Madrid (HM), Spain

Development and verification of predictive biomarkers for oncology. We are researching new methods that will enable personalized medicine in accordance with tumour molecular profile information.


Alberto Acedo
AC-Gen Reading Life S.L., Valladolid, Spain

We present the draft genome sequences of Corynebacterium kroppenstedtii CNM633/14 and CNM632/14, multidrug-resistant and antibiotic-sensitive isolates from granulomatous mastitis samples.

Emma Lundman
Rikshospital Norway

Experiences with Ion PGM™ and Ion Chef™ systems with Torrent Suite™ Variant Caller and Ion Reporter™ data analysis for inherited disease research.


Nienke Van der Stoep
Clinical Genetics, Leiden University Medical Center, The Netherlands

Development and experience with custom Ion AmpliSeq™ gene panels in clinical genetics research.


Alexander Pavlov
Parseq Lab, St.Petersburg, Russia

We developed a tool for detection of small-size CNVs in the heterozygous state, using custom Ion AmpliSeq targeted sequencing and Ion Reporter analysis.Our algorithm could also be used for QC of samples with imbalanced amplicon content.

Kaddour Chabane
Laboratory for molecular biology and cytogenetics, Centre Hospitalier Lyon Sud, France

Development and evaluation of an Ion AmpliSeq™ community gene panel for the analysis of acute myelocytic leukaemia (AML).


Joaquin Martinez
Hospital 12 de Octubre, Madrid, Spain

Development of new molecular diagnostic and prognostic tests for different molecular alterations observed in haematological malignancies.


Gema Moreno
MD Anderson Cancer Center, Madrid, Spain


Martin De Boer
Sanquin Blood Supply Foundation, Amsterdam, The Netherlands

Ion AmpliSeq technolgoy has enabled discovery of a mutation that explains an absence of a protein (mass spec data) in a disease research project, which has remained elusive for over 10 years.


Elena Kostryukova
Scientific Research Institute of Physical-Chemical Medicine, Federal Medical & Biological Agency, Russia

We will present analysis of prostate cancer samples using the Ion AmpliSeq Exome Kit on the Ion Proton system. In addition, we present whole-transcriptome sequencing of tumour and normal samples using the Ion Total RNA-Seq kit on the Ion Proton system. Work is supported by the Ministry of Education and Science of the Russian Federation (grant No. 14.607.21.0068, ID RFMEFI60714X0068).

Susana Häggqvist
Uppsala Genome Centre, Sweden

Susana will present her experiences and data on a range of genetic study applications using the latest Ion Torrent technology.


Nadja Valtheva
Systems Pathology & High-Throughput Genomics Laboratory Institute of Surgical Pathology, University Hospital Zurich

Our work is aimed at systematically identifying the combinations and the chronological order of molecular alterations that accumulate during endometrial cancer progression.


John Rossen
Faculty of Medical Sciences, University of Groningen, The Netherlands

Presenting 16S metagenomics using the Ion PGM™ System in microbiology and outbreak management.


Veeranagouda Yaligara
Sanofi R&D, Vitry, France

MicroRNAs (miRNAs) present in tissues and biofluids are emerging as sensitive and specific safety biomarkers. Macaca fascicularis (Cynomolgus monkey) is used in the pharmaceutical industry especially in drug safety evaluation. Although genome data is available for M. fascicularis, miRNAs have not been thoroughly described in this species. Talk provides insight on miRNAs in M. fascicularis.

Giuseppe Viglietto
Magna Graecia University, Catanzaro, Italy

Presenting the use of Ion AmpliSeq™ Comprehensive Cancer Panel reveling new potential targets in Colorectal Cancer.


Stefania Tommasi
I.R.C.C.S. Istituto Oncologico "G. Paolo II", Bari, Italy

Shareing her expience with Ion AmpliSeq™ RNA Lung Fusion Panel to select patients eligible to ALK inhibitor treatment.


Silvia Gimondi
Fondazione I.R.C.C.S. Istituto Nazionale Tumori, Milano, Italy

Ion semiconductor sequencing for the evaluation of IgH gene rearrangements: feasibility and applications in B-cell malignancies.


Edoardo Giacopuzzi
University of Brescia, Brescia, Italy

AmpliSeq™ Exome on the Ion Proton™ System: what's new with Hi-Q?


Thomas Rio Frio
Genoma, Switzerland

Fetal aneuploidies are detected through the bioinformatic analysis of the sequencing of circulating cell-free maternal and fetal DNA present in the blood plasma using next generation sequencing. High-throughput processing of samples with high reproducibility and reduced probability of sample mixing requires a fully automatised process with complete tracking of samples and reagents from DNA extraction until the sequencing and bioinformatic analysis.

Sean Kennedy
Institute Pasteur, Paris, France

Sean will be speaking about the evaluation of new technologies for microbial studies.


Francesco Crea
Premaitha Health, Manchester, UK

Detection of trisomies from cfDNA using the Ion Proton System.